Monoclonal Antibody Infusion for Cancer Therapy from China
Biotechnologically produced monoclonal antibodies like rituximab for therapeutic infusion in lymphoma treatment. HTS 3002.90.52 includes such immunological products prepared for therapeutic uses. They target specific cancer cells via immune regulation.
Duty Rate — China → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Provide stability data for ambient vs refrigerated shipping to optimize logistics
• Confirm orphan drug status for potential duty exemptions or expedited review
• Document biotech origin to distinguish from chemical synthetics in Chapter 29